|Bid||16.88 x 1400|
|Ask||0.00 x 3000|
|Day's Range||16.69 - 17.04|
|52 Week Range||14.59 - 25.96|
|Beta (3Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.50|
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $16.64, marking a +0.79% move from the previous day.
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
PALM BEACH, Florida, March 14, 2019 /CNW/ -- Recent upgrades in international and domestic regulations regarding clinical trials, are both designed to protect patients, but also to upgrade the 'new normal' procedures in clinical trial quality and more efficient approaches to clinical trial design, conduct, oversight, recording and reporting. Internationally, the key regulation is Good Clinical Practice, which is: "Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human subjects. Compliance with GCP assures that the rights, safety, and well-being of trial subjects are protected and that the clinical trial data are credible.
With the medical marijuana market expected to hit US$ 40 billion by 2024, and the potential for cannabis compounds to displace opiates, traditional drugmakers are betting big on weed
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.78, marking a +0.19% move from the previous day.
OxyContin maker Purdue Pharma LP and two other drugmakers on Friday lost a bid to delay a landmark trial set for May in a multibillion-dollar lawsuit by Oklahoma's attorney general accusing them of helping fuel an opioid abuse and overdose epidemic in the state. Cleveland County District Judge Thad Balkman's decision was a win for the state, even as one of the lawyers for the state said Purdue had "threatened" to file for bankruptcy rather than face the first trial to result from around 2,000 lawsuits nationally. Reuters, citing people familiar with the matter, on Monday reported that Stamford, Connecticut-based Purdue, owned by members of the wealthy Sackler family, was exploring filing for Chapter 11 bankruptcy protection.
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Growth drivers In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Comparing the tax rateIn its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) has guided for a non-GAAP adjusted tax rate of 10% for
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Free cash flow projections Bausch Health Companies (BHC) and Teva Pharmaceutical (TEVA) reported free cash flow of $1.27 billion and $1.79 billion, respectively,
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Expense guidance for fiscal 2018 In its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) guided for adjusted non-GAAP SG&A
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Flector®1 Patch, 1.3 %, in the U.S. Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions. “The launch of our authorized generic of Flector® Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” said Brendan O’Grady, EVP and Head of North America Commercial.
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Earnings guidance for fiscal 2019In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) guided for fiscal 2019 non-GAAP adjusted EBITDA of
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?Stock price movementsOn February 26, Bausch Health Companies (BHC) closed at $23.16, 0.81% lower than its previous closing price, 60.39% higher than its 52-week low of $14.44, and 18.59%
Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.